Cytori Therapeutics Inc (CYTX) Shares Down 9.8%
Cytori Therapeutics Inc (NASDAQ:CYTX) shares were down 9.8% during trading on Wednesday . The stock traded as low as $0.28 and last traded at $0.32. Approximately 1,052,204 shares traded hands during trading, an increase of 33% from the average daily volume of 791,155 shares. The stock had previously closed at $0.36.
Several research analysts recently commented on CYTX shares. B. Riley reiterated a “buy” rating and set a $2.30 price objective on shares of Cytori Therapeutics in a research note on Wednesday, May 10th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 12th. Maxim Group set a $10.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Saturday, May 13th. Finally, ValuEngine lowered shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
The stock’s 50-day moving average price is $0.46 and its 200 day moving average price is $1.04. The company’s market cap is $11.21 million.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The firm’s quarterly revenue was down 18.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.43) EPS. Equities research analysts expect that Cytori Therapeutics Inc will post ($0.60) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. lifted its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the quarter. Vanguard Group Inc. owned about 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.82% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.